ARTICLE | Company News
Ardelyx, Sanofi deal
March 3, 2014 8:00 AM UTC
Ardelyx granted Sanofi exclusive, worldwide rights to develop and commercialize Ardelyx's RDX002 program of solute carrier family 34 sodium phosphate member 2 ( SLC34A2; NaPi2b) inhibitors. Ardelyx...